Comparative Analysis of Inflammatory Bowel Disease Presentation and Severity in Pediatric vs. Adult Patients

Rasha Sulaiman Abdelraheem; Ali Mohammed Fadhil Aldulaimi; Nabeeha Najatee Akram

doi:10.54133/ajms.v9i1.2039

Authors

Rasha Sulaiman Abdelraheem Department of Pediatrics, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0001-6452-2121
Ali Mohammed Fadhil Aldulaimi Department of Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0002-0997-1714
Nabeeha Najatee Akram Department of Pediatrics, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0001-8964-8943

DOI:

https://doi.org/10.54133/ajms.v9i1.2039

Keywords:

Crohn’s disease, Pancolitis, Ulcerative Colitis

Abstract

Background: Inflammatory bowel disease (IBD) encompasses chronic conditions that cause inflammation in the gastrointestinal tract, most notably Crohn’s disease and ulcerative colitis. Both diseases present with variable clinical features, with significant differences observed between pediatric and adult populations. Objective: To examine the clinical presentation, severity, and disease progression of IBD in children compared to adults. Methods: A retrospective observational analysis included patients diagnosed with Crohn’s disease or ulcerative colitis at a tertiary gastroenterology center over a 6-month period. Patients were allocated into pediatric patients (diagnosed at <15years) and adults (diagnosed at >15years). The collected data included demographical data, including age, sex, and body mass index. Clinical data including symptom duration, presenting symptoms, disease severity, and extraintestinal manifestations (EIMs). Results: A total of 100 patients (50 children and 50 adults) with confirmed diagnoses of IBD were included. While there was no significant difference in gender distribution between the child IBD and adult IBD cohorts (p=0.272), the BMI was significantly higher in adults (p=0.028). The clinical presentations were comparable between groups, except for higher duration of symptoms and weight loss in adults (p=0.012, 0.048, respectively). No statistically significant difference was observed in the frequency of EIMs, disease severity, and disease distribution between groups, except for a higher trend for pancolitis in child IBD (p=0.036). Conclusions: Pediatric patients with IBD may present with a more aggressive disease course and require tailored treatment strategies. Understanding these age-related differences is critical for optimizing early diagnosis, management, and long-term care of IBD patients.

Downloads

Download data is not yet available.

References

Shen B, (Ed.), Introduction and classification of inflammatory bowel diseases. Atlas of Endoscopy Imaging in Inflammatory Bowel Disease, 2020. doi: 10.1016/B978-0-12-814811-2.00001-3. DOI: https://doi.org/10.1016/B978-0-12-814811-2.00001-3

Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18. doi: 10.1038/s41575-020-00360-x. DOI: https://doi.org/10.1038/s41575-020-00360-x

Lim CT, Salazar E, Tan MTK, Chan W. Inflammatory bowel disease – An update for primary care physicians. Singapore Fam Physician. 2022;48. doi: 10.33591/sfp.48.1.uo1. DOI: https://doi.org/10.33591/sfp.48.1.uo1

Verstockt B, Bressler B, Martinez-Lozano H, McGovern D, Silverberg MS. Time to revisit disease classification in inflammatory bowel disease: Is the current classification of inflammatory bowel disease good enough for optimal clinical management? Gastroenterology. 2022;162. doi: 10.1053/j.gastro.2021.12.246. DOI: https://doi.org/10.1053/j.gastro.2021.12.246

Murugesan S, Kumar M, Saadaoui M, Elhag DA, Hendaus MA, Ibrahim N, et al. P322 mycobiome signature in pediatric patients with inflammatory bowel disease. J Crohns Colitis. 2023;17. doi: 10.1093/ecco-jcc/jjac190.0452. DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0452

Nori W, Akram NN, Al-Kaabi MM. Probiotics in women and pediatrics health: A narrative review. Al-Anbar Med J. 2023;19. doi: 10.33091/amj.2023.138442.1021. DOI: https://doi.org/10.33091/amj.2023.138442.1021

Choi S, Moon W. Pediatric-onset inflammatory bowel disease: What are different from adult in the treatment? Korean J Gastroenterol. 2021;77. doi: 10.4166/kjg.2021.067. DOI: https://doi.org/10.4166/kjg.2021.067

Nori W, Najatee Akram N, Al-Kaabi MM, Al-Ani RM, Pantazi AC. Innovative gut microbiome-targeted strategies: A promising frontier for pediatric inflammatory bowel disease. New Emirates Med J. 2025;5:02506882356553. doi: 10.2174/0102506882356553250306050102. DOI: https://doi.org/10.2174/0102506882356553250306050102

El-Matary W, Bernstein CN. Cancer risk in pediatric-onset inflammatory bowel disease. Front Pediatr. 2020;8. doi: 10.3389/fped.2020.00400. DOI: https://doi.org/10.3389/fped.2020.00400

Kumagai H, Shimizu T, Iwama I, Hagiwara SI, Kudo T, Takahashi M, et al. A consensus statement on health-care transition for childhood-onset inflammatory bowel disease patients. Pediatrics Int. 2022;64. doi: 10.1111/ped.15241. DOI: https://doi.org/10.1111/ped.15241

Zelinkova Z, Kadleckova B, Cierna I, Podmanicky D. P392 behavior of childhood-onset inflammatory bowel disease through adulthood. J Crohns Colitis. 2024;18. doi: 10.1093/ecco-jcc/jjad212.0522. DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0522

Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric crohn’s disease activity index. J Pediatr Gastroenterol Nutr. 1991;12. doi: 10.1097/00005176-199105000-00005. DOI: https://doi.org/10.1002/j.1536-4801.1991.tb10268.x

Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index: National cooperative Crohn’s disease study. Gastroenterology. 1976;70. doi: 10.1016/S0016-5085(76)80163-1. DOI: https://doi.org/10.1016/S0016-5085(76)80163-1

Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study. Gastroenterology. 2007;133. doi: 10.1053/j.gastro.2007.05.029. DOI: https://doi.org/10.1053/j.gastro.2007.05.029

Hassan WNM, Al-Kaabi MM, Akram NN, Kassim MAK, Pantazi AC. Probiotics for inflammatory bowel disease; A deep dive into their impact on disease course and associated health risks. Curr Med Chem. 2024. doi: 10.2174/0109298673314861240429072352. DOI: https://doi.org/10.2174/0109298673314861240429072352

Bouhuys M, Lexmond WS, van Rheenen PF. Pediatric inflammatory bowel disease. Pediatrics. 2023;151. doi: 10.1542/peds.2022-058037. DOI: https://doi.org/10.1542/peds.2022-058037

Khavkin AI, Nalyotov AV, Fedulova EN, Marchenko NA. Inflammatory bowel diseases in children: diagnostic algorithms and modern therapy strategies. Voprosy Dietologii. 2023;13:32–42. doi: 10.20953/2224-5448-2023-3-32-42. DOI: https://doi.org/10.20953/2224-5448-2023-3-32-42

Yablokova EA, Dzhabarova AK, Lokhmatov MM, Gorelov AV, Krutikhina SB, Erokhina MI, et al. Extraintestinal manifestations in inflammatory bowel diseases in children, a modern view of the problem. Exp Clin Gastroenterol. 2023. doi: 10.31146/1682-8658-ecg-209-1-165-177. DOI: https://doi.org/10.31146/1682-8658-ecg-209-1-165-177

Atia O, Shosberger A, Focht G, Ledder O, Lev-Tzion R, Navon D, et al. Development and validation of the IBD-REFER criteria: Early referral for suspected inflammatory bowel diseases in adults and children. Crohns Colitis 360. 2020;2(2):otaa027. doi: 10.1093/crocol/otaa027. DOI: https://doi.org/10.1093/crocol/otaa027

Carbonell FRM, Chandan OC. Body mass index at presentation of inflammatory bowel disease in children. Pediatr Gastroenterol Hepatol Nutr. 2020;23. doi: 10.5223/PGHN.2020.23.5.439. DOI: https://doi.org/10.5223/pghn.2020.23.5.439

Parente P, Mastracci L, Vanoli A, Fassan M, Pastore M, Bossa F, et al. Pattern-based histologic approach in very early onset IBD: Main features and differential diagnosis. Adv Anat Pathol. 2022;29. doi: 10.1097/PAP.0000000000000323. DOI: https://doi.org/10.1097/PAP.0000000000000323

Granot M, Kopylov U, Loberman-Nachum N, Krauthammer A, Abitbol CM, Ben-Horin S, et al. Differences in disease characteristics and treatment exposures between paediatric and adult-onset inflammatory bowel disease using a registry-based cohort. Aliment Pharmacol Ther. 2024;60:1435–1446. doi: 10.1111/apt.18264. DOI: https://doi.org/10.1111/apt.18264

Martinez EC, Ng WL, Joseph M, Guzman A, Chávez LM, Htoo M, et al. Human β -defensin 2 isoforms expression on pediatric IBD. Inflamm Bowel Dis. 2024;30. doi: 10.1093/ibd/izae020.088. DOI: https://doi.org/10.1093/ibd/izae020.088

Sandberg K, Duarte H, Stolfi A, Saeed S. Diagnosis changes in pediatric IBD: Data from the IMPROVECARENOW registry. Inflamm Bowel Dis. 2021;27. doi: 10.1093/ibd/izaa347.104. DOI: https://doi.org/10.1093/ibd/izaa347.104

Onidi FM, Mocci G, Elisei W, Corpino M, Orru’ G, Marongiu A, et al. N34 Transition of inflammatory bowel disease patients from pediatric to adult care: A single-center ten-years experience. J Crohns Colitis. 2024;18. doi: 10.1093/ecco-jcc/jjad212.1406. DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1406

Ruel J, Ruane D, Mehandru S, Gower-Rousseau C, Colombel JF. IBD across the age spectrum - Is it the same disease? Nat Rev Gastroenterol Hepatol. 2014;11. doi: 10.1038/nrgastro.2013.240. DOI: https://doi.org/10.1038/nrgastro.2013.240

Hyams JS, Davis S, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, et al. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. Lancet Gastroenterol Hepatol. 2017;2. doi: 10.1016/S2468-1253(17)30252-2. DOI: https://doi.org/10.1016/S2468-1253(17)30252-2

Kosinsky RL, Gonzalez MM, Saul D, Barros LL, Sagstetter MR, Fedyshyn Y, et al. The FOXP3+ pro-inflammatory T cell: A potential therapeutic target in Crohn’s disease. Gastroenterology. 2024;166. doi: 10.1053/j.gastro.2024.01.007. DOI: https://doi.org/10.1053/j.gastro.2024.01.007